The last decade has seen considerable advancement in the treatment options available to patients with rheumatoid arthritis (RA) through development of oral, small molecules that target and inhibit Janus kinases (JAKi). These drugs have a rapid onset action, disrupting kinase/signal transducer activator transcription pathway preventing production cytokines involved inflammatory processes. They p...